EATG » Vaccines

Vaccines

VBI Vaccines completes vaccination in PROTECT Phase 3 clinical study for Sci-B-Vac® hepatitis B vaccine

-- Vaccination complete in 1,537 subjects in PROTECT Phase 3 study -- No vaccine-related adverse events have been observed to-date -- Top-line data expected mid-2019 October 16, 2018: VBI Vaccines…

No, the HPV vaccine does not lead to riskier sexual behaviors in girls

Many parents of adolescent girls have resisted the human papillomavirus vaccine for fear it will have negative behavioral consequences. The human papillomavirus (HPV) vaccine is not associated with an increase…

CDC report highlights need for meningococcal vaccine among HIV-infected MSM

A new report published by the Centers for Disease Control and Prevention (CDC) details epidemiological findings on increased rates of meningococcal disease among men who have sex with men (MSM).…

FDA approves expanded use of Gardasil 9 to include individuals 27 through 45 years old

The U.S. Food and Drug Administration today (October 5) approved a supplemental application for Gardasil 9 (Human Papillomavirus (HPV) 9-valent Vaccine, Recombinant) expanding the approved use of the vaccine to…

TB vaccine halves risk of disease in people with latent TB

A vaccine against tuberculosis (TB) reduced the risk of developing active TB in HIV-negative people with latent TB infection by 54% in a large phase 2b study published last month…

IAVI announces clinical trial of next-generation HIV vaccine candidate designed to induce antibodies to block HIV infection

Phase I trial to evaluate safety and immunogenicity of vaccine candidate engineered to elicit targeted immune response against HIV NEW YORK – OCTOBER 9, 2018 – The International AIDS Vaccine…

GSK candidate vaccine helps prevent active pulmonary TB in HIV negative adults in phase II study

Publication of primary results in the New England Journal of Medicine shows positive impact of innovative vaccine technology in clinical trial conducted in tuberculosis endemic regions. LONDON (25 September 2018)…

Therapeutic vaccine effectively reduces viral load in chronic hepatitis B

In treatment-naïve patients with chronic hepatitis B virus (HBV) infection, a therapeutic vaccine candidate (NASVAC) more effectively reduced viral load compared with pegylated interferon (Peg-IFN), according to study results published…

Special antibodies could lead to HIV vaccine

Around one percent of people infected with HIV produce antibodies that block most strains of the virus. These broadly acting antibodies provide the key to developing an effective vaccine against…

Inovio and Korean partner dose 1st subject in trial to develop world’s first vaccine to prevent hepatitis C infection

While new therapies have made hepatitis C a curable infection, no preventive vaccine has ever been approved PLYMOUTH MEETING, Pa., and SEOUL, Korea, Sept. 04, 2018 -- Inovio Pharmaceuticals, Inc.…

1 2 3 19